{"pmid":32292848,"pmcid":"PMC7151394","title":"COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies.","text":["COVID-19 for the Cardiologist: A Current Review of the Virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies.","The coronavirus disease-2019 (COVID-19), a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), has reached pandemic status. As it spreads across the world, it has overwhelmed healthcare systems, strangled the global economy and led to a devastating loss of life. Widespread efforts from regulators, clinicians and scientists are driving a rapid expansion of knowledge of the SARS-CoV2 virus and the COVID-19 disease. We review the most current data with a focus on our basic understanding of the mechanism(s) of disease and translation to the clinical syndrome and potential therapeutics. We discuss the basic virology, epidemiology, clinical manifestation, multi-organ consequences, and outcomes. With a focus on cardiovascular complications, we propose several mechanisms of injury. The virology and potential mechanism of injury form the basis for a discussion of potential disease-modifying therapies.","JACC Basic Transl Sci","Atri, Deepak","Siddiqi, Hasan K","Lang, Joshua","Nauffal, Victor","Morrow, David A","Bohula, Erin A","32292848"],"abstract":["The coronavirus disease-2019 (COVID-19), a contagious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV2), has reached pandemic status. As it spreads across the world, it has overwhelmed healthcare systems, strangled the global economy and led to a devastating loss of life. Widespread efforts from regulators, clinicians and scientists are driving a rapid expansion of knowledge of the SARS-CoV2 virus and the COVID-19 disease. We review the most current data with a focus on our basic understanding of the mechanism(s) of disease and translation to the clinical syndrome and potential therapeutics. We discuss the basic virology, epidemiology, clinical manifestation, multi-organ consequences, and outcomes. With a focus on cardiovascular complications, we propose several mechanisms of injury. The virology and potential mechanism of injury form the basis for a discussion of potential disease-modifying therapies."],"journal":"JACC Basic Transl Sci","authors":["Atri, Deepak","Siddiqi, Hasan K","Lang, Joshua","Nauffal, Victor","Morrow, David A","Bohula, Erin A"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292848","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jacbts.2020.04.002","keywords":["ACE2, angiotensin-converting enzyme 2","ARDS, acute respiratory distress syndrome","CDC, Centers for Disease Control","CFR, case fatality rate","COVID-19","COVID-19, coronavirus disease-2019","Cardiovascular","CoV, coronavirus","DIC, disseminated intravascular coagulation","ER, endoplasmic reticulum","ICU, intensive care unit","SARS-CoV1 or 2, severe acute respiratory syndrome coronavirus-1 or -2","SARS-CoV2","SOFA, sequential organ failure assessment","TMPSS2, trasmembrane serine protease-2","Treatments","Virology","hsCRP, high sensitivity c-reactive protein"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664266295686725632,"score":8.233237,"similar":[{"pmid":32301766,"title":"Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.","text":["Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.","Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.","J Cardiovasc Pharmacol","Buckley, Leo F","Cheng, Judy W M","Desai, Akshay","32301766"],"abstract":["Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy."],"journal":"J Cardiovasc Pharmacol","authors":["Buckley, Leo F","Cheng, Judy W M","Desai, Akshay"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301766","week":"202016|Apr 13 - Apr 19","doi":"10.1097/FJC.0000000000000840","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Aldosterone"],"_version_":1664357978495516672,"score":243.44778},{"pmid":32219363,"title":"Potential Effects of Coronaviruses on the Cardiovascular System: A Review.","text":["Potential Effects of Coronaviruses on the Cardiovascular System: A Review.","Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level. Coronaviruses are known to affect the cardiovascular system. We review the basics of coronaviruses, with a focus on COVID-19, along with their effects on the cardiovascular system. Observations: Coronavirus disease 2019 can cause a viral pneumonia with additional extrapulmonary manifestations and complications. A large proportion of patients have underlying cardiovascular disease and/or cardiac risk factors. Factors associated with mortality include male sex, advanced age, and presence of comorbidities including hypertension, diabetes mellitus, cardiovascular diseases, and cerebrovascular diseases. Acute cardiac injury determined by elevated high-sensitivity troponin levels is commonly observed in severe cases and is strongly associated with mortality. Acute respiratory distress syndrome is also strongly associated with mortality. Conclusions and Relevance: Coronavirus disease 2019 is associated with a high inflammatory burden that can induce vascular inflammation, myocarditis, and cardiac arrhythmias. Extensive efforts are underway to find specific vaccines and antivirals against SARS-CoV-2. Meanwhile, cardiovascular risk factors and conditions should be judiciously controlled per evidence-based guidelines.","JAMA Cardiol","Madjid, Mohammad","Safavi-Naeini, Payam","Solomon, Scott D","Vardeny, Orly","32219363"],"abstract":["Importance: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19) has reached a pandemic level. Coronaviruses are known to affect the cardiovascular system. We review the basics of coronaviruses, with a focus on COVID-19, along with their effects on the cardiovascular system. Observations: Coronavirus disease 2019 can cause a viral pneumonia with additional extrapulmonary manifestations and complications. A large proportion of patients have underlying cardiovascular disease and/or cardiac risk factors. Factors associated with mortality include male sex, advanced age, and presence of comorbidities including hypertension, diabetes mellitus, cardiovascular diseases, and cerebrovascular diseases. Acute cardiac injury determined by elevated high-sensitivity troponin levels is commonly observed in severe cases and is strongly associated with mortality. Acute respiratory distress syndrome is also strongly associated with mortality. Conclusions and Relevance: Coronavirus disease 2019 is associated with a high inflammatory burden that can induce vascular inflammation, myocarditis, and cardiac arrhythmias. Extensive efforts are underway to find specific vaccines and antivirals against SARS-CoV-2. Meanwhile, cardiovascular risk factors and conditions should be judiciously controlled per evidence-based guidelines."],"journal":"JAMA Cardiol","authors":["Madjid, Mohammad","Safavi-Naeini, Payam","Solomon, Scott D","Vardeny, Orly"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32219363","week":"202013|Mar 23 - Mar 29","doi":"10.1001/jamacardio.2020.1286","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1663352135060815873,"score":238.68675},{"pmid":32269893,"pmcid":"PMC7138423","title":"A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).","text":["A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19).","Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic.","Cureus","Kakodkar, Pramath","Kaka, Nagham","Baig, M N","32269893"],"abstract":["Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments. The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated. Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed. The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed. The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic."],"journal":"Cureus","authors":["Kakodkar, Pramath","Kaka, Nagham","Baig, M N"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32269893","week":"202015|Apr 06 - Apr 12","doi":"10.7759/cureus.7560","keywords":["ace2","ards","chloroquine","covid-19","lopinavir and ritonavir","mrna-1273 vaccine","pandemic","remdesivir (gs-5734)","sars-cov-2","severe acute respiratory infection"],"source":"PubMed","locations":["COVID19"],"topics":["Treatment","Diagnosis"],"weight":1,"e_drugs":["Ibuprofen","Ascorbic Acid","Vitamin D"],"_version_":1663620083064242178,"score":230.26108},{"pmid":32293003,"title":"Hypertension, the renin-angiotensin system, and` the risk of lower respiratory tract infections and lung injury: implications for COVID-19.","text":["Hypertension, the renin-angiotensin system, and` the risk of lower respiratory tract infections and lung injury: implications for COVID-19.","Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic.","Cardiovasc Res","Kreutz, Reinhold","Algharably, Engi Abd El-Hady","Azizi, Michel","Dobrowolski, Piotr","Guzik, Tomasz","Januszewicz, Andrzej","Persu, Alexandre","Prejbisz, Aleksander","Riemer, Thomas Gunther","Wang, Ji-Guang","Burnier, Michel","32293003"],"abstract":["Systemic arterial hypertension (referred to as hypertension herein) is a major risk factor of mortality worldwide, and its importance is further emphasized in the context of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection referred to as COVID-19. Patients with severe COVID-19 infections commonly are older and have a history of hypertension. Almost 75% of patients who have died in the pandemic in Italy had hypertension. This raised multiple questions regarding a more severe course of COVID-19 in relation to hypertension itself as well as its treatment with renin-angiotensin system (RAS) blockers, e.g. angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We provide a critical review on the relationship of hypertension, RAS, and risk of lung injury. We demonstrate lack of sound evidence that hypertension per se is an independent risk factor for COVID-19. Interestingly, ACEIs and ARBs may be associated with lower incidence and/or improved outcome in patients with lower respiratory tract infections. We also review in detail the molecular mechanisms linking the RAS to lung damage and the potential clinical impact of treatment with RAS blockers in patients with COVID-19 and a high cardiovascular and renal risk. This is related to the role of angiotensin-converting enzyme 2 (ACE2) for SARS-CoV-2 entry into cells, and expression of ACE2 in the lung, cardiovascular system, kidney, and other tissues. In summary, a critical review of available evidence does not support a deleterious effect of RAS blockers in COVID-19 infections. Therefore, there is currently no reason to discontinue RAS blockers in stable patients facing the COVID-19 pandemic."],"journal":"Cardiovasc Res","authors":["Kreutz, Reinhold","Algharably, Engi Abd El-Hady","Azizi, Michel","Dobrowolski, Piotr","Guzik, Tomasz","Januszewicz, Andrzej","Persu, Alexandre","Prejbisz, Aleksander","Riemer, Thomas Gunther","Wang, Ji-Guang","Burnier, Michel"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293003","week":"202016|Apr 13 - Apr 19","doi":"10.1093/cvr/cvaa097","keywords":["Angiotensin","COVID-19","Cardiovascular","Hypertension","Lung"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664266295703502849,"score":230.23569},{"pmid":32234466,"title":"Coronavirus disease 2019 (COVID-19): current status and future perspective.","text":["Coronavirus disease 2019 (COVID-19): current status and future perspective.","The coronavirus disease 2019 (COVID-19) is derived from Wuhan city, Hubei province of China, has spread quickly in 72 countries to date. COVID-19 is caused by a novel coronavirus SARS-CoV2, previously 2019-nCoV. At present, the newly identified SARS-CoV2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged COVID-19 is urgently needed to elucidate their pathogenic mechanisms and epidemiological characteristics, and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV2 and characteristics of COVID-19, such as etiology, pathogenesis and epidemiological characteristics.","Int J Antimicrob Agents","Li, Heng","Liu, Shang-Ming","Yu, Xiao-Hua","Tang, Shi-Lin","Tang, Chao-Ke","32234466"],"abstract":["The coronavirus disease 2019 (COVID-19) is derived from Wuhan city, Hubei province of China, has spread quickly in 72 countries to date. COVID-19 is caused by a novel coronavirus SARS-CoV2, previously 2019-nCoV. At present, the newly identified SARS-CoV2 has caused a large number of deaths with tens of thousands of confirmed cases worldwide, posing a serious threat to public health. However, there are no clinically approved vaccines or specific therapeutic drugs available for COVID-19. Intensive research on the newly emerged COVID-19 is urgently needed to elucidate their pathogenic mechanisms and epidemiological characteristics, and to identify potential drug targets, which will contribute to the development of effective prevention and treatment strategies. Hence, this review will focus on recent progress regarding the structure of SARS-CoV2 and characteristics of COVID-19, such as etiology, pathogenesis and epidemiological characteristics."],"journal":"Int J Antimicrob Agents","authors":["Li, Heng","Liu, Shang-Ming","Yu, Xiao-Hua","Tang, Shi-Lin","Tang, Chao-Ke"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234466","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.ijantimicag.2020.105951","keywords":["COVID-19","Coronavirus","Pneumonia","SARS-CoV2"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Mechanism","Treatment"],"weight":1,"_version_":1663352135446691841,"score":227.29565}]}